National Bank of Canada’s Actinium Pharmaceuticals ATNM Stock Holding History

National Bank of Canada’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1K	Buy	1,021 +166	+19%	+$197	﹤0.01%	2671
2025 Q4	$1.16K	Hold	855	–	–	﹤0.01%	2612
2025 Q3	$1.37K	Hold	855	–	–	﹤0.01%	2620
2025 Q2	$1.2K	Hold	855	–	–	﹤0.01%	2673
2025 Q1	$1.37K	Hold	855	–	–	﹤0.01%	2549
2024 Q4	$1.08K	Hold	855	–	–	﹤0.01%	2641
2024 Q3	$1.61K	Hold	855	–	–	﹤0.01%	2376
2024 Q2	$6.1K	Hold	855	–	–	﹤0.01%	2222
2024 Q1	$7.44K	Hold	855	–	–	﹤0.01%	2233
2023 Q4	$4.54K	Hold	855	–	–	﹤0.01%	2324
2023 Q3	$4.75K	Hold	855	–	–	﹤0.01%	2360
2023 Q2	$6.32K	Hold	855	–	–	﹤0.01%	2290
2023 Q1	$8.04K	Hold	855	–	–	﹤0.01%	2194
2022 Q4	$9.03K	Hold	855	–	–	﹤0.01%	2210
2022 Q3	$6K	Hold	855	–	–	﹤0.01%	2297
2022 Q2	$4K	Hold	855	–	–	﹤0.01%	2451
2022 Q1	$4K	Hold	855	–	–	﹤0.01%	2584
2021 Q4	$5K	Buy	+855	New	+$6.41K	﹤0.01%	2522

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

National Bank of Canada's ATNM Position: Q1 2026 in Review

National Bank of Canada increased its Actinium Pharmaceuticals (ATNM) stake by 19% in Q1 2026, buying an estimated $197 and bringing the position to 1,021 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2671.

National Bank of Canada first reported a position in ATNM in Q4 2021 and has held it in 18 quarters since. The position peaked at $9.03K in Q4 2022. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

National Bank of Canada held 1,021 shares of Actinium Pharmaceuticals worth $1K as of Q1 2026.
National Bank of Canada bought 166 Actinium Pharmaceuticals shares in Q1 2026, an estimated $197.
Actinium Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2671 holding.
National Bank of Canada first reported a position in Actinium Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
National Bank of Canada's Actinium Pharmaceuticals position peaked at $9.03K in Q4 2022.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.